GREAT-2 was a phase II, placebo-controlled trial evaluating gremubamab, a bispecific monoclonal antibody, for chronic Pseudomonas aeruginosa infection in bronchiectasis. As part of our ATS 2025 coverage, Dr Merete Long discusses how this targeted therapy disrupts the vicious cycle of infection and inflammation, trial outcomes including significant bacterial load reduction and improved quality of life, and the broader implications for future treatment strategies.

In this Q&A, Professors David Price and David Halpin discuss their ATS 2025 abstract on improving COPD outcomes through a digital adherence support package. They explore the MAGNIFY trial's design, including how an EMR-driven algorithm identified high-risk patients and how a pharmacist-led intervention combined with a digital inhaler device significantly reduced treatment failure in a real-world primary care setting.

The current treatment landscape for severe asthma faces major challenges despite biologic advances targeting type 2 inflammation. Current biomarkers like BEC and FeNO inadequately predict treatment response. To optimize precision medicine, improved molecular phenotyping and novel non-invasive biomarkers are urgently needed to better identify asthma endotypes and guide therapy.

Artificial intelligence is no longer a futuristic concept in respiratory care — it's already here, reshaping how we diagnose and manage asthma. In this insightful interview, Dr Alan Kaplan shares how AI is helping bridge long-standing gaps in asthma diagnosis, adherence, and disease control. From apps that can tell the difference between asthma and COPD, to smart inhalers that track medication use and predict exacerbations, Dr Kaplan explores the real-world potential of AI — and the challenges that come with it. He also weighs in on whether AI scribe software can enhance the patient–physician relationship, and what excites him most about the road ahead.

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted ...

GSK has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application for depemokimab, an investigational monoclonal antibody targeting interleukin-5 (IL-5), for two indications: as an add-on maintenance treatment for asthma in patients aged 12 and older with type 2 inflammation characterized by an eosinophilic phenotype, and as an add-on treatment for adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

The European Commission has approved dupilumab (Regeneron and Sanofi)) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils.

Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and ...

Approximately half of all smokers will develop chronic obstructive pulmonary disease (COPD), with a disease progression over several years before the spirometric threshold for diagnosis is reached.1 There is, therefore, a clear benefit in identifying patients with COPD as early ...